Rocuronium Bromide Injection, Solution
Product Images NDC 0409-9558

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 0409-9558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Rocuronium Bromide (Rocuronium 01)

Chemical structure of Rocuronium Bromide showing the molecular framework with characteristic rings and functional groups including quaternary ammonium and bromide ion.*

FDA Label Image

Figure 1: Time To 80% Or Greater Block Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 02)

A box plot chart titled 'Time to 80% or greater Block vs. Initial Dose of Rocuronium Bromide by Age Group' depicting the relationship between the initial dose of Rocuronium Bromide (in mg/kg) and the time in minutes to achieve 80% or greater neuromuscular block. The data is separated into three age groups: 18-64 years, 65 years and older, and 1-12 years. The chart shows median, 25th and 75th percentiles, and individual values for each dose within these age groups.*

FDA Label Image

Figure 2: Duration Of Clinical Effect Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 03)

A box plot chart showing the duration of clinical effect in minutes versus initial dose of Rocuronium Bromide by age group. The graph displays median, 25th and 75th percentiles, and individual values for age groups 18-64 years, 65 years and older, 3 months to 1 year, and 1-12 years with corresponding dose ranges in mg/kg on the x-axis and duration in minutes on the y-axis.*

FDA Label Image

Figure 3: Duration Of Clinical Effect Vs. Number Of Rocuronium Bromide Maintenance Doses, By Dose (Rocuronium 04)

A line graph titled 'Duration of Clinical Effect vs. Number of Rocuronium Bromide Maintenance Doses, by Dose' depicting duration in minutes (y-axis) against dose number (x-axis from 0 to 6). Two dose groups, 0.1 mg/kg and 0.15 mg/kg, are shown with lines representing duration changes across doses, annotated with sample sizes (N=29 and N=13 respectively). The higher dose group shows longer durations with slight variation across doses.*

FDA Label Image

Hospira Logo (Rocuronium 05)

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Label for Rocuronium Bromide Injection 50 mg/5 mL (10 mg/mL) multiple dose vial. The injection solution is for intravenous use, containing rocuronium bromide and sodium acetate, distributed by Hospira, Inc. The label includes a warning that the drug is a paralyzing agent requiring facilities for artificial respiration, storage instructions, and dosage information.*

FDA Label Image

Principal Display Panel (5 mL Vial Box)

Packaging label for Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) solution for intravenous use. The label indicates 10 x 5 mL multiple dose vials. The product is distributed by Hospira, Inc. and made in the Netherlands. Warnings include Paralylzing Agent and respiratory-related precautions. Storage instructions specify refrigeration (2 to 8°C) with no freezing.*

FDA Label Image

Principal Display Panel (10 mL Vial Label)

Label for Rocuronium Bromide Injection 10 mg/mL, a multiple dose vial containing 100 mg per 10 mL, for intravenous use only. The label includes warnings for use as a paralyzing agent and storage instructions. Distributed by Hospira, Inc., Lake Forest, IL, USA. NDC 0409-9558-31 is displayed, along with dosage and storage details.*

FDA Label Image

Principal Display Panel (10 mL Vial Box)

Packaging label for Rocuronium Bromide Injection 10 mg/mL (100 mg/10 mL) in 10 x 10 mL multiple dose vials. The label includes warnings about paralysis and respiratory arrest, storage instructions, and manufacturer information for Hospira, Inc. It also features the NDC 0409-9558-10 and a barcode on the package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.